MVA Mosaic HIV vaccine - Janssen Vaccines and Prevention

Drug Profile

MVA Mosaic HIV vaccine - Janssen Vaccines and Prevention

Alternative Names: Modified Vaccinia Ankara Mosaic HIV vaccine; MVA-Mosaic

Latest Information Update: 31 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Crucell Holland
  • Developer Beth Israel Deaconess Medical Center; Janssen Vaccines and Prevention B.V
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II HIV infections

Most Recent Events

  • 24 Jul 2017 Immunogenecity and adverse events data from a phase I/II trial in HIV infections (Prevention) released by Johnson and Johnson
  • 01 Sep 2016 Phase-I/II clinical trials in HIV infections (Combination therapy, Treatment-experienced) in Thailand (IM) (NCT02919306)
  • 01 Nov 2015 Crucell Holland completes a phase I trial in HIV infections (Prevention) in USA (IM) (NCT02218125)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top